Market Cap 385.07M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.00
Volume 2,841,800
Avg Vol 2,545,936
Day's Range N/A - N/A
Shares Out 77.01M
Stochastic %K 9%
Beta 0.87
Analysts Strong Sell
Price Target $22.38

Latest News on ALT

Altimmune to Host Virtual R&D Day on March 13, 2025

Mar 6, 2025, 7:30 AM EST - 27 days ago

Altimmune to Host Virtual R&D Day on March 13, 2025


Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 2:24 PM EST - 4 weeks ago

Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript


Final Trade: WST, BTC, GLD, ALT

Feb 14, 2025, 6:32 PM EST - 6 weeks ago

Final Trade: WST, BTC, GLD, ALT

GLD BTC WST


Altimmune Could Find A Partner For Its Phase 3 Exercise

Dec 30, 2024, 11:42 AM EST - 3 months ago

Altimmune Could Find A Partner For Its Phase 3 Exercise


Altimmune Added to Nasdaq Biotechnology Index

Dec 19, 2024, 7:30 AM EST - 3 months ago

Altimmune Added to Nasdaq Biotechnology Index


Altimmune 2025: Redefining Obesity And MASH Treatment

Dec 16, 2024, 3:14 AM EST - 3 months ago

Altimmune 2025: Redefining Obesity And MASH Treatment


Altimmune CEO on what's next for its experimental obesity drug

Dec 3, 2024, 6:04 PM EST - 4 months ago

Altimmune CEO on what's next for its experimental obesity drug


Altimmune to Participate at Two Upcoming Investor Conferences

Nov 26, 2024, 7:30 AM EST - 4 months ago

Altimmune to Participate at Two Upcoming Investor Conferences


Final Trade: C, NVDA, XLF, ALT

Nov 19, 2024, 6:29 PM EST - 4 months ago

Final Trade: C, NVDA, XLF, ALT

NVDA XLF C


Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:00 AM EST - 5 months ago

Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript


Consider Buying Potential Takeover Target Altimmune

Oct 2, 2024, 2:48 PM EDT - 6 months ago

Consider Buying Potential Takeover Target Altimmune


Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 9:03 AM EDT - 8 months ago

Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript


Altimmune to Participate at Leerink Partners Therapeutics Forum

Jul 2, 2024, 7:30 AM EDT - 9 months ago

Altimmune to Participate at Leerink Partners Therapeutics Forum